Home » Stocks » Mustang Bio

Mustang Bio, Inc. (MBIO)

Stock Price: $2.83 USD 0.02 (0.71%)
Updated Oct 22, 2020 4:00 PM EDT - Market closed
After-hours: $2.89 +0.06 (2.12%) Oct 22, 7:58 PM

Stock Price Chart

Key Info

Market Cap 121.64M
Revenue (ttm) -50,000
Net Income (ttm) -52.83M
Shares Out 42.14M
EPS (ttm) -1.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 22, 2020
Last Price $2.83
Previous Close $2.81
Change ($) 0.02
Change (%) 0.71%
Day's Open 2.81
Day's Range 2.57 - 2.85
Day's Volume 3,084,695
52-Week Range 1.78 - 4.85

More Stats

Market Cap 121.64M
Enterprise Value 51.60M
Earnings Date (est) Nov 17, 2020
Ex-Dividend Date n/a
Shares Outstanding 42.14M
Float 31.65M
EPS (basic) -1.27
EPS (diluted) -1.27
FCF / Share -0.86
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 2.22M
Short Ratio 1.28
Short % of Float 7.01%
Beta 1.57
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 2.50
Revenue -50,000
Operating Income -51.56M
Net Income -52.83M
Free Cash Flow -38.52M
Net Cash 70.05M
Net Cash / Share 1.63
Gross Margin n/a
Operating Margin 103,120.00%
Profit Margin n/a
FCF Margin 77,040.00%
ROA -34.02%
ROE -74.16%
ROIC -295.70%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(218.02% upside)
Current: $2.83
Target: 9.00
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Operating Income-45.89-31.22-31.79-11.36
Net Income-46.39-30.66-31.29-12.65
Shares Outstanding36.0626.9525.2511.03
Earnings Per Share-1.29-1.14-1.24-1.15
Operating Cash Flow-33.58-19.24-12.95-4.13
Capital Expenditures-2.35-6.87-0.42-
Free Cash Flow-35.93-26.11-13.37-4.13
Cash & Equivalents62.4134.5761.4827.50
Total Debt15.53---
Net Cash / Debt46.8834.5761.4827.50
Book Value51.6536.4059.8324.28
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Mustang Bio, Inc.
Country United States
Employees 51
CEO Manuel Litchman

Stock Information

Ticker Symbol MBIO
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MBIO


Mustang Bio, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develop MB-107, a gene therapy program, potential curative treatment for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. Its ex vivo lentiviral gene therapy is in two Phase 1/2 clinical trials. The company also develops MB-102, a heterodimeric interleukin-3-receptor for acute myeloid leukemia; MB-106 for immunotherapy of B-cell lymphomas; MB-104, an NK cell receptor regulating immune functions; MB-101 CAR T cell program for glioblastoma; MB-103 CAR T for glioblastoma multiforme (GBM) and metastatic breast cancer to brain; MB-105 CAR T for prostate and pancreatic cancers; and MB-108, a next-generation oncolytic herpes simplex virus. It has a license agreement with Nationwide Children's Hospital for the development of an oncolytic virus for treating GBM; and Beth Israel Deaconess Medical Center, Inc. to perform research relating to gene editing. The company was incorporated in 2015 and is headquartered in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.